Vor Biopharma (NASDAQ:VOR) Trading Down 5.1% – What’s Next?

Vor Biopharma Inc. (NASDAQ:VOR) shares dropped 5.1% during trading on Monday . The company traded as low as $19.79 and last traded at $19.5450. Approximately 179,481 shares changed hands during trading, a decline of 83% from the average daily volume of 1,076,841 shares. The stock had previously closed at $20.59.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen lowered Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Wells Fargo & Company assumed coverage on Vor Biopharma in a research report on Thursday, March 19th. They set an “overweight” rating and a $30.00 target price for the company. Weiss Ratings raised Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 30th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research report on Thursday, April 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $31.00 price objective on shares of Vor Biopharma in a research note on Monday, May 18th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.25.

Vor Biopharma Price Performance

The stock’s 50-day simple moving average is $15.15 and its 200 day simple moving average is $14.67.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. Equities research analysts predict that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Insiders Place Their Bets

In other Vor Biopharma news, Director Ra Capital Management, L.P. sold 165,150 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total value of $2,604,415.50. Following the transaction, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. The trade was a 6.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders sold 2,153,646 shares of company stock worth $34,896,602. Company insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in VOR. RA Capital Management L.P. increased its position in Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. increased its holdings in shares of Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Vor Biopharma in the 4th quarter worth approximately $33,275,000. Paradigm Biocapital Advisors LP acquired a new position in Vor Biopharma during the 4th quarter worth $22,890,000. Finally, NEXTBio Capital Management LP acquired a new position in Vor Biopharma during the 4th quarter worth $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).